Study Summary
This trial will test the safety and effectiveness of 2 influenza vaccines against common flu strains.
- Influenza
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
6 Primary · 2 Secondary · Reporting Duration: Baseline, Days 121 and 181
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
5 Treatment Groups
Egg-based Quadrivalent Influenza Vaccine (Age Group 18-50 years)
1 of 5
Adjuvanted Quadrivalent Influenza Vaccine (Age Group 65-80 years)
1 of 5
Inactivated Influenza Vaccine (Age Group 65-80 years)
1 of 5
mRNA-1010 (Age Group 18-50 years)
1 of 5
mRNA-1010 (Age Group 65-80 years)
1 of 5
Active Control
Experimental Treatment
125 Total Participants · 5 Treatment Groups
Primary Treatment: mRNA-1010 (Age Group 18-50 years) · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 80 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Does this research offer a program for individuals above the age of thirty-five?
"This trail has an upper age limit of 80 and a lower threshold requiring the participant to be above legal adulthood." - Anonymous Online Contributor
Am I eligible to partake in this medical research?
"The scope of this medical investigation is targeting 125 individuals suffering from the flu, aged between 18 and 80. Notably, participants must have a body mass index (BMI) between 18 kg/m^2 to 40 kg/m^2 at screening. In addition, female patients of reproductive age are obligated to take a pregnancy test on day one; they need to practice safe contraception or abstain from sexual activities in the preceding 28 days prior to injection and until 3 months post-vaccination. Moreover, breastfeeding women may not participate in this trial." - Anonymous Online Contributor
How many participants are being enrolled in this research initiative?
"Affirmative. Data hosted on clinicaltrials.gov attests that this medical trial, originally made available on November 2nd 2022, is currently recruiting participants. 125 patients are being sought from a single location." - Anonymous Online Contributor
Are there remaining vacancies for this trial that individuals can apply to?
"As indicated on clinicaltrials.gov, this trial is actively recruiting patients with the original posting date being November 2nd 2022 and last edited on November 4th of that same year." - Anonymous Online Contributor
Has the FDA sanctioned mRNA-1010 for use in individuals aged 18 to 50?
"With the available evidence, our team at Power has cautiously assigned mRNA-1010 a safety rating of 2. This is due to Phase 2 data indicating there are some parameters around safety that have been established yet efficacy remains unconfirmed." - Anonymous Online Contributor